TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars

Benzinga Logo Benzinga By Vandana Singh
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars

Novo Nordisk's stock has declined 41% year-to-date due to reduced sales guidance and competitive challenges from Eli Lilly in the weight-loss drug market, with Lilly's broader pipeline and Zepbound gaining market share.

Insights
NVO   negative

Stock down 41% YTD, reduced sales guidance, losing market share in weight-loss drugs, patent expiration concerns